Senior/Research Associate, Single Cell Genomics at NewLimit

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Bachelor’s degree in cell biology, molecular biology, or a related natural science or industry experience
2+ years of work experience in a cell or molecular biology laboratory (academic or industry)
Experience with standard molecular biology workflows (e.g., nucleic acid extraction, PCR, NGS library construction, library quantification and QC)
Experience with cell and sample handling (e.g., mammalian cell culture, primary tissue dissociation, nuclei isolation, cryopreservation)

Responsibilities

Collaborate with our Epigenetic Editing team to perform large-scale, single cell perturbation experiments with custom chemistries
Perform state-of-the-art single cell profiling experiments to map epigenetic features of age-related disease and evaluate interventions
Measure the safety & efficacy of reprogramming medicines with frontier genomics methods
Isolate, culture, and prepare cells for single cell profiling experiments

Skills

molecular biology

cell culture

nucleic acid extraction

PCR

NGS library construction

library QC

nuclei isolation

cryopreservation

tissue dissociation

single cell genomics

10x Genomics

NewLimit

Medicines for healthspan extension via epigenetics

About NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

South San Francisco, CaliforniaHeadquarters

2022Year Founded

$38.9MTotal Funding

SERIES_ACompany Stage

Biotechnology, HealthcareIndustries

11-50Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Risks

Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.

Ethical concerns and regulatory scrutiny may delay product approvals.

Competition from similar biotech firms could impact NewLimit's market share.

Differentiation

NewLimit focuses on epigenetic reprogramming to extend human healthspan.

The company uses single-cell genomics and machine learning for drug discovery.

NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Upsides

Increased interest in epigenetic reprogramming boosts NewLimit's market potential.

Machine learning aids in identifying novel drug candidates for age-related diseases.

FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

Land your dream remote job 3x faster with AI

Try Jobo Free